272 related articles for article (PubMed ID: 18215091)
1. Ribonucleases as novel chemotherapeutics : the ranpirnase example.
Lee JE; Raines RT
BioDrugs; 2008; 22(1):53-8. PubMed ID: 18215091
[TBL] [Abstract][Full Text] [Related]
2. Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies.
Beck AK; Pass HI; Carbone M; Yang H
Future Oncol; 2008 Jun; 4(3):341-9. PubMed ID: 18518759
[TBL] [Abstract][Full Text] [Related]
3. Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase.
Costanzi J; Sidransky D; Navon A; Goldsweig H
Cancer Invest; 2005; 23(7):643-50. PubMed ID: 16305992
[TBL] [Abstract][Full Text] [Related]
4. Ranpirnase: amphibian ribonuclease A, P-30 protein-alfacell.
Drugs R D; 2007; 8(2):120-4. PubMed ID: 17324010
[TBL] [Abstract][Full Text] [Related]
5. Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy.
Lee I
Expert Opin Biol Ther; 2008 Jun; 8(6):813-27. PubMed ID: 18476793
[TBL] [Abstract][Full Text] [Related]
6. [Onconase: a ribonuclease with antitumor activity].
Zwolińska M; Smolewski P
Postepy Hig Med Dosw (Online); 2010 Feb; 64():58-66. PubMed ID: 20173221
[TBL] [Abstract][Full Text] [Related]
7. Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma.
Porta C; Paglino C; Mutti L
Biologics; 2008 Dec; 2(4):601-9. PubMed ID: 19707441
[TBL] [Abstract][Full Text] [Related]
8. Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma.
Pavlakis N; Vogelzang NJ
Expert Opin Biol Ther; 2006 Apr; 6(4):391-9. PubMed ID: 16548765
[TBL] [Abstract][Full Text] [Related]
9. Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes.
Ardelt W; Shogen K; Darzynkiewicz Z
Curr Pharm Biotechnol; 2008 Jun; 9(3):215-25. PubMed ID: 18673287
[TBL] [Abstract][Full Text] [Related]
10. Highly efficient destruction of squamous carcinoma cells of the head and neck by photochemical internalization of Ranpirnase.
Liebers N; Holland-Letz T; Welschof M; Høgset A; Jäger D; Arndt MAE; Krauss J
J Exp Ther Oncol; 2017 Nov; 12(2):113-120. PubMed ID: 29161778
[TBL] [Abstract][Full Text] [Related]
11. An EGF receptor targeting Ranpirnase-diabody fusion protein mediates potent antitumour activity in vitro and in vivo.
Kiesgen S; Arndt MAE; Körber C; Arnold U; Weber T; Halama N; Keller A; Bötticher B; Schlegelmilch A; Liebers N; Cremer M; Herold-Mende C; Dyckhoff G; Federspil PA; Jensen AD; Jäger D; Kontermann RE; Mier W; Krauss J
Cancer Lett; 2015 Feb; 357(1):364-373. PubMed ID: 25434798
[TBL] [Abstract][Full Text] [Related]
12. Cancer chemotherapy--ribonucleases to the rescue.
Leland PA; Raines RT
Chem Biol; 2001 May; 8(5):405-13. PubMed ID: 11358688
[TBL] [Abstract][Full Text] [Related]
13. Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity.
Rutkoski TJ; Raines RT
Curr Pharm Biotechnol; 2008 Jun; 9(3):185-9. PubMed ID: 18673284
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of activation-induced apoptosis of lymphocytes by the cytotoxic ribonuclease onconase (Ranpirnase).
Halicka DH; Pozarowski P; Ita M; Ardelt WJ; Mikulski SM; Shogen K; Darzynkiewicz Z
Int J Oncol; 2002 Dec; 21(6):1245-50. PubMed ID: 12429974
[TBL] [Abstract][Full Text] [Related]
15. A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity.
Wu Y; Mikulski SM; Ardelt W; Rybak SM; Youle RJ
J Biol Chem; 1993 May; 268(14):10686-93. PubMed ID: 8486718
[TBL] [Abstract][Full Text] [Related]
16. A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells.
Ramos-Nino ME; Littenberg B
Mol Cancer Ther; 2008 Jul; 7(7):1871-9. PubMed ID: 18606715
[TBL] [Abstract][Full Text] [Related]
17. The interdependence between catalytic activity, conformational stability, and cytotoxicity of onconase.
Schulenburg C; Ardelt B; Ardelt W; Arnold U; Shogen K; Ulbrich-Hofmann R; Darzynkiewicz Z
Cancer Biol Ther; 2007 Aug; 6(8):1233-9. PubMed ID: 17637563
[TBL] [Abstract][Full Text] [Related]
18. Aspects of the cytotoxic action of ribonucleases.
Arnold U
Curr Pharm Biotechnol; 2008 Jun; 9(3):161-8. PubMed ID: 18673281
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer.
Vogelzang NJ; Aklilu M; Stadler WM; Dumas MC; Mikulski SM
Invest New Drugs; 2001; 19(3):255-60. PubMed ID: 11561684
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.
Mikulski SM; Costanzi JJ; Vogelzang NJ; McCachren S; Taub RN; Chun H; Mittelman A; Panella T; Puccio C; Fine R; Shogen K
J Clin Oncol; 2002 Jan; 20(1):274-81. PubMed ID: 11773179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
